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ABSTRACT 
The purpose of this integrative review was to identify, critique, and synthesize the maternal and 
neonatal evidence on the prenatal use of probiotics and prebiotics to inform perinatal health 
professionals. A comprehensive literature search resulted in 37 studies of prenatal probiotics and 1 on 
antepartal prebiotics published from 1990 through 2011 that reported maternal, fetal, and/or neonatal 
outcomes. The methodologic quality of the studies reviewed was high, although investigators used 
different probiotic combinations and inconsistently reported perinatal clinical outcomes. The 
extraction of perinatal outcome variables resulted in identification of 9 maternal and 5 neonatal 
categories. Prenatal probiotics significantly reduced the incidence of bacterial vaginosis, increased 
colonization with vaginal Lactobacillus and intestinal Lactobacillus rhamnosus, altered immune markers 
in serum and breast milk, improved maternal glucose metabolism, and reduced the incidence of 
gestational diabetes and preeclampsia. Antepartally, probiotics were associated with significantly 
higher counts of Bifidobacterium and Lactococcus lactis (healthy intestinal flora) in neonatal stool. 
Prenatal prebiotics significantly increased maternal intestinal Bifidobacterium. No adverse events were 
reported and there was evidence of safety and tolerance of prenatal probiotics and prebiotics in the 
scientific investigations reviewed. It is recommended that in future investigations of prenatal 
probiotics researchers explicitly report maternal and neonatal outcomes. 
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Complementary and integrative therapies (CIT) have received a great deal of attention from 
consumers.1 Probiotics and prebiotics are considered food2 and are readily available over the counter 
to women and families as CITs. A variety of readily available fermented milk products contain live 
active probiotic bacteria in varying amounts. While numerous commercially available prenatal vitamins 
now contain prebiotics and probiotics, the scientific evidence supporting these formulations is lacking. 
Furthermore, some providers are recommending prenatal probiotic supplementation to their clients to 
reduce Group B Streptococcus colonization,3 although no clinical trials to date support this practice. In 
addition, numerous infant formulas now contain probiotics and prebiotics, but evidence to support 
incorporating them is lacking as well.4 Perinatal nurses and providers need detailed information about 
the implications of probiotics and/or prebiotics for the woman and neonate so that accurate histories 
are obtained and providers can offer the best information to women and families who are considering 
prenatal dietary supplements.1 
While the scientific information on this topic is available in international journals, it is essentially 
absent from the perinatal nursing literature. However, it is well documented that prenatal probiotics 
reduce the incidence and severity of allergic disease in children of mothers who consumed these 
products.5 While the pediatric benefits of prenatal probiotics are important, a gap remains in the 
knowledge about the maternal and neonatal effects and whether these products really impact clinical 
outcomes. 
BACKGROUND 
Probiotics are live microorganisms which, when administered in adequate amounts, confer a health 
benefit on the host.2 Most commonly available probiotic supplements contain Lactobacillus and/or 
Bifidobacterium, which are part of the normal human microbiome.6 Probiotics enhance the healthy 
microbiota of the gastrointestinal and genitourinary tracts in a number of ways.7,8 They produce lactic, 
acetic, and other acids that lower the pH in these environments, thus impeding the growth of bacterial 
pathogens on mucosal surfaces like the intestines and vagina.8 Probiotics also appear to stimulate the 
production of numerous substances that work together to improve healthy microflora and displace 
harmful bacteria.8 These substances include vitamins, bacteriocins, enzymes, and biosurfactants that 
alter the surface tension and reduce pathogen adherence to the mucosa.8–10 Probiotics are thought to 
work synergistically with the host immune system to stimulate specific lymphocytes, cytokines, and IgG 
and IgA antibodies to fight infection.8 
Prebiotics are not live organisms11 but are fermented food ingredients that can be used by bacteria to 
confer health benefits upon the host.12 Prebiotics serve as food for species of Lactobacillus and/or 
Bifidobacterium, encouraging growth of these beneficial bacteria which in turn may inhibit the growth 
of pathogenic bacteria where they have colonized.8 
PURPOSE 
An integrative review was chosen as the most robust approach to allow the inclusion of the diverse 
methods used in the body of scientific literature.13 The purpose of this integrative review was to 
identify, critique, and synthesize the perinatal evidence on prenatal probiotics and prebiotics. Maternal 
and neonatal outcomes derived from the literature are comprehensively detailed in this review. The 
goal is to review the evidence as it specifically applies to perinatal practice.13 
METHODS 
Medical Literature Analysis and Retrieval System (MEDLINE), Cumulative Index to Nursing and Allied 
Health Literature (CINAHL), and the Cochrane Library databases were searched using the terms: 
probiotics, prebiotics, pregnancy, and women’s health, for articles published from 1990 through 
December 2011. Additional hand searches were conducted using reference lists of articles. This process 
yielded 251 articles that were screened to identify scientific investigations of prenatal probiotics or 
prebiotics that reported maternal and/or neonatal outcomes. The resulting 38 studies that met 
criteria, published between 1993 and 2011, were reviewed. 
Data were extracted from each article in a systematic manner, using an adaptation of a previously 
published instrument.14 During the data evaluation stage, each study was assessed for quality using the 
Oxford definitions for levels of evidence.15 The level of evidence ratings for the 36 individual studies 
are presented in Table 1. Further during the data evaluation process, it was observed that many of the 
studies could be clustered into research collectives on the basis of specific cross-references, common 
trial registration numbers, countries in which the research was done, co-authorships, and/or use of the 
exact same sample. These observations raised concerns about overrepresenting primary data 
sources.13 Table 1 is organized by study design, according to identified research collectives (lettered A-
H), when applicable. The linkages between studies were not always clear; therefore, the authors 
indicated in Table 1 which studies made explicit versus vague connections to the parent study. Prenatal 
probiotic interventions were used in a total of 31 randomized placebo controlled trials,16–46 while 
prebiotics were explored in only one.47 The remaining 4 investigations of probiotics included 1 quasi-
experiment,48 2 prospective cohort studies,49,50 and 1 observational study.51 
Two systematic reviews/meta-analyses on prenatal probiotics were included in this integrative review; 
both were assessed as level 1 evidence. The studies that appeared in the systematic reviews/meta-
analyses and that were analyzed in this integrative review are indicated by symbols in Table 1. Dugoua 
et al52 included 8 randomized controlled trials (RCTs) of prenatal probiotics and focused on the safety 
of Lactobacillus and Bifidobacterium species related to 3 specific outcomes: cesarean section, birth 
weight, and gestational age. Naaktgeboren53 analyzed 25 RCTs for the outcomes of perinatal probiotics 
on intestinal microflora, immunity, and maternal and infant nutrient utilization. Then the researcher 
conducted meta-analyses using 10 of the RCTs focusing on 3 specific pediatric outcomes: (1) atopic 
dermatitis, (2) skin prick testing, and (3) allergic sensitization. However, neither article incorporated 
the full range of RCTs, the quasi-experiment, the prospective cohort studies, and the observational 
investigation included in this integrative review. In addition, neither article fully addressed the 
maternal and neonatal outcomes.52,53 
  















       
A  Kalliomaki16 2001d  Finland  159  3  DB  Yes  1b 
Ab  Rautava17 2000d,e  Finland  159  3  DB  Yes  1b 
Ab  Rinne18 2005  Finland  96  3  DB  Yes  1b 
Ac  Gueimonde19 2007d  Finland  53  3  N/A  Yes  1b 
Ab  Kalliomaki20 2008e  Finland  49  3  DB  Yes  1b 
Ab  Luoto, Kalliomaki21 2010  Finland  113  3  DB  Yes  1b 
Bc  Kukkonen22 2006d  Finland  87  3  DB  Yes  1b 
B  Kukkonen23 2007d,e  Finland  1223  3  DB  Yes  1b 
Bb  Kukkonen24 2008  Finland  1223  3  DB  Yes  1b 
Bc  Kuitunen25 2009e  Finland  891  3  DB  Yes  1b 
C  Piirainen26 2006  Finland  140  1  DB  Yes  1b 
Cb  Kaplas27 2007d  Finland  30  1  DB-SB  Yes 1b 
Cb  Huurre28 2008e  Finland  171  1  DB  Yes  1b 
Cb  Aaltonen29 2008  Finland  256  1  DB-SB  Yes  1b 
Cb  Laitinen30 2009  Finland  256  1  DB-SB  Yes  1b 
Cb  Luoto, Laitinen31 2010  Finland  256  1  DB-SB  Yes  1b 
Cb  Aaltonen32 2011  Finland  256  1  DB-SB  Yes  1b 
Cb  Ilmonen33 2011  Finland  256  1  DB-SB  Yes  1b 
Db  Kopp34 2007  Germany  105  3  DB  Yes  1b 
D  Kopp35 2008e  Germany  105  3  DB  Yes  1b 
Eb  Boyle36 2008  Australia  73  3  DB  Yes  1b 
Eb  Lahtinen37 2009  Australia  122  3  DB  Yes  1b 
Fc  Prescott38 2008  New Zealand  105  3  DB  Yes  1b 
Fb  Wickens39 2008e  New Zealand  474  3  DB  Yes  1b 
G  Abrahamsson40 2007d,e  Sweden  232  3  DB  Yes  1b 
Gb  Bottcher41 2008e  Sweden  109  3  DB  Yes  1b 
 Nishijima42 2005d  Japan  24  N/A  N/A  Yes  3b 
 Niers43 2009e  Netherlands  156  3  DB  Yes  1b 
 Dotterud44 2010  Norway  415  3  DB  Yes  1b 
 Allen45 2011  United 
Kingdom  
454 3 DB Yes 1b 
 Asemi46 2011  Iran 70 3 SB Yes 1b 
 Shadid47 2007  Germany 48 2 DB Yes 4 
Quasi experiment        
 Neri48 1993  Israel 84 N/A N/A Yes 3b 
Prospective cohort 
studies 
       
Hb Brantsaeter49 2011  Norway 33 399 1 N/A N/A 2b 
Hb Myhre50 2011  Norway 18 888 1 N/A N/A 2b 
Observational study 
 
       
 Schultz51 2004  Germany 9 3 N/A N/A 3b 
Abbreviations: DB, double blind; N/A, not available; SB, single blinded control group. 
aOxford Center for Evidence-based Medicine Levels of Evidence.15 
bExplicit reference to parent study. 
cVague reference to parent study. 
dIncluded in Dugoua et al52 systematic review & meta-analyses. 




In this section, an overview of the studies reviewed is provided and participant demographics across 
the studies are summarized. Probiotic routes, strains, and dosing are explained. Outcome 
categorization is introduced, and the maternal and neonatal outcomes are described in detail. 
Overview of studies reviewed 
Data from studies conducted in 11 countries in which women were given probiotics during pregnancy 
were synthesized. A representative sample size was estimated from the 7 research collectives that 
conducted RCTs; together these totaled nearly 2000 pregnant women who were likely exposed to 
probiotics. Moreover, 2 prospective cohort studies (research collective H) included more than 33 000 
women with varying amounts of ingested probiotics in their diets.49,50 Twenty-four pregnant women 
were exposed to prebiotics in 1 study reviewed.47 
Demographic characteristics of prenatal participants 
Participant characteristics were underreported in the articles reviewed. Investigators in 4 studies 
performed in Scandinavia and Northern Europe reported the sample race as Caucasian.30–32,35 While 
researchers from New Zealand provided details of their diverse sample,39 those from Japan and Iran 
did not report the race(s) of their study subjects.42,46 Of the investigations that included the percent of 
participants who were college educated,25,26,29–33,45 the median percent who attended college was 
70.6% for the probiotic and prebiotic groups and 68.1% for controls. Among those who reported mean 
ages,25–27,29–36,38,41,43–48 the results were 30.4 years for probiotic and prebiotic group study subjects and 
31.3 years for women in the control groups. Overall, from the partial information available, the 
participants appeared to include mature, highly educated adults from primarily homogeneous groups. 
Although all the studies reviewed included healthy pregnant women, investigators in 19 had selected 
samples of women specifically with a risk of atopy (a predisposition toward developing allergic 
hypersensitivity reactions)54 to examine whether prenatal probiotics or prebiotics would reduce 
subsequent development of allergic disease in offspring.16,17,21–25,28,35–41,43–45,47 This risk was defined by 
the researchers as having at least 1 first degree relative with atopic dermatitis or eczema, allergic 
rhinitis, and/or asthma. The purposeful sampling of women with atopic risk suggests that the 
outcomes of prenatal probiotics and prebiotics could be different in women without this risk. 
Furthermore, studies that preferentially included women with atopic risk also tended to measure long-
term pediatric outcomes, beyond the neonatal period, and thus exceeded the time parameter 
established for this integrative review. 
Routes, strains, and doses of study interventions 
Because probiotics are live cultured microbial food supplements,55 the dose is measured by colony 
forming units (CFUs) per milliliter, calculated by dividing the number of colonies, multiplied by the 
dilution on a Petri dish, by the volume of the culture on the same plate.56 In the 35 individual probiotic 
studies reviewed, doses ranged from 1 × 107 to 2 × 1010 CFUs (see Table 2). Most of the probiotic 
studies used 1 or more strains of Lactobacillus, and several added at least 1 Bifidobacterium. These 
products are available over the counter. 
In 27 of the studies, probiotics were administered as capsules and 2 others used oil dilutions.40,41 In the 
remaining 6 studies, shown in Table 3, probiotic interventions were in the form of milk or yogurt 
products. In addition, one researcher studied a water-soluble prebiotic supplement containing both 
galacto-oligosaccharides and long-chain fructo-oligosaccharides derived from cow’s milk.47 
Investigators did not provide rationale to explain their choices of probiotic or prebiotic in any of the 
studies reviewed. Most of the investigators began the intervention during the third trimester and 
continued at least until birth. Six reports were unclear concerning treatment duration,26,27,42,48–50 and a 
seventh study only gave probiotics between 28 and 37 weeks’ gestation.46 
  
Table 2. Probiotic species and doses in studies reviewed 
Lactobacillus (CFUs) Bifidobacterium (CFUs) Other species (CFUs) Reference numbers 
L. rhamnosus (2.0 ×  109 −
2.0 ×  1010) 
  16, 17, 18, 19, 20, 21, 34, 
35, 36, 37, 51 
L. reuteri (1.0 ×  108)    40, 41 
L. rhamnosus (6.0 ×  109)  B. animalis (9.0 ×  109)   38, 39 
L. rhamnosus (1.0 ×  109 −
1.0 ×  1010) 
B. animalis subsp lactis (1.0 ×  10 −
1.0 ×  1010) 
 26, 27, 28, 29, 30, 31, 32, 
33 
L. rhamnosus (1.0 × 1010)  B. breve (2.0 × 108 bid)  Propionibacterium freudenreichii subsp 
shermanii (2.0 × 109 bid) 
22, 23, 24, 25 
L. salivarius (6.25 ×  109)  
L. paracasei (1.25 ×  109) 
B. animalis (1.25 × 109) 
B. bifidum (1.25 ×  109) 
 45 
[No Lactobacillus]  B. animalis (1 ×  109) 
B. bifidum (1 × 109) 
Lactococcus lactis (1 ×  109)  43 
Abbreviations: B, Bifidobacterium; bid, twice daily; CFUs, colony forming units; L, Lactobacillus; subsp, subspecies. 
Table 3. Yogurts and fermented milk probiotic products studied 
Country Brand 
name 


















Milk Oral No-zero 
low = 13 mL per day 
high = 85 mL per day 
N/A L. acidophilus (1.0 × 108)/mL 
L. rhamnosus (1.0 ×  108)/mL 
 
B. lactis 
(5.0 × 109) 
44, 49, 50 
Norway  
 
Cultura Milk Oral No-zero  
low = 13 mL per day 
high = 85 mL per day 
N/A L. acidophilus (1 × 108)/mL 
 






N/A Yogurt Oral 200 g per day 4.3-
4.5 
L. acidophilus (1.0 × 107)/ 200g B. animalis 
(1.0 ×  107) 
46 
Abbreviations: B, Bifidobacterium; CFUs, colony forming units; L, Lactobacillus; N/A, not available; subsp, subspecies. 
  
Categorizing outcomes 
All discrete outcomes reported in the scientific investigations were extracted. First, the outcomes were 
broadly classified as maternal or neonatal. During the data reduction process for this integrative 
review,13 the first 2 authors conducted a content analysis to identify each discrete perinatal study 
outcome. Commonalities between studies were identified and combined into categories. These logical 
categories provided meaningful descriptions of the major maternal and neonatal outcomes. The third 
author confirmed that the categories accurately reflected the data. This inclusive and comprehensive 
process resulted in a total of 14 categories. The 9 maternal outcome categories identified were mode 
of birth, vaginal flora composition preterm labor, blood pressures and preeclampsia prevention, 
glucose metabolism, body mass index (BMI) and weight gain, gastrointestinal outcomes, breast milk 
composition, and maternal immunomarkers. The neonatal findings are detailed in 5 categories: 
gestational age at birth, fetal cord blood, Apgar scores, anthropometric measures, and gastrointestinal 
outcomes. All findings were reported according to these 14 outcome categories and are identified 
according to article reference numbers in Table 4. 
In the following sections, the statistically significant and clinically relevant perinatal outcomes are 
presented according to the categories. Although most maternal and neonatal outcomes were 
statistically nonsignificant, a comprehensive presentation is provided in adherence to the principles of 
the integrative review process.13 Furthermore, some nonsignificant findings have clinical relevance for 
perinatal health professionals as the findings may suggest the safety of the intervention and facilitate 
complete disclosure of information by providers to women and their families. 
Maternal outcomes 
In the following sections, the 9 statistically significant and clinically relevant maternal outcomes are 
described. For ease of reference, all the outcome categories are summarized in Table 4. This includes 
those studies with nonsignificant findings. 
Mode of birth 
In most of the 20 investigations that reported cesarean rates in the study and control groups, between-
group differences were not statistically analyzed. However, according to one meta-analysis,52 there 
was no significant difference in mode of birth in the probiotic groups when compared with controls 
(OR = 0.88; 95% CI: 0.65-1.19; P = 4). Therefore, based on current limited evidence prenatal probiotics 
do not appear to impact the mode of birth. 
Vaginal flora and pH 
One of the mechanisms of action of probiotics is the acidification of mucosal surfaces like the vagina, 
thus inhibiting the growth of pathogens. Vaginal flora or pH were explored in only 3 studies; 2 of which 
reported statistically significant findings. Neri et al48 conducted a 3-group comparison of an 
intravaginal yogurt intervention for treating bacterial vaginosis, compared to vaginal acetic acid 
(tampon soaked in 10-15 mL of 5% acetic acid), and a nontreatment control group. All 32 women in the 
yogurt group reported symptom relief after 2 days of treatment. At both 1 and 2 months 
posttreatment, women in the yogurt group had a significantly higher bacterial vaginosis cure rate than 
those in the acetic acid (P = .04) and the control (P < .0005) groups. Nishijima et al42 studied the impact 
of probiotics on the vaginal flora of pregnant women and found that probiotic treatment (n = 32) 
significantly increased vaginal Lactobacillus colonization (P = .025) and eliminated pathogenic bacteria 
(Gardnerella and Corynebacterium) (no P value provided). Overall, the results suggest that probiotics 
reduced the symptoms and presence of bacterial vaginosis and other pathogens within 1 month of 
administration. Vaginal flora findings beyond the presence of bacterial vaginosis were not explored in 
any of the investigations reviewed. 
Table 4. Summary of findings according to outcome category and reference numbersa of studies 
Reviewed 
Outcome Category Any significant 
findings 
Exclusively nonsignificant findings 
Maternal outcomes   
Mode of birth (cesarean sections rates) N/A 17, 19, 20, 21, 22, 23, 24, 25, 30, 31, 34, 
35, 36, 37, 38, 39, 40, 43, 47, 52 
Vaginal flora and pH  42, 48 47 
Preterm labor  42 and 48b, 50 N/A 
Blood pressures and preeclampsia 
prevention 
49 26, 29 
Glucose metabolism  30, 31, 32 N/A 
Body mass index and weight gain  49, 50 26, 27, 29, 30, 32, 33, 46 
Gastrointestinal measures   37, 47 19, 30, 51 
Breast milk composition   17, 38, 41 18, 28, 37 
Maternal immunomarkers  36, 46 N/A 
Neonatal Outcomes   
Gestational age at birth  
 
N/A 16, 17, 18, 20, 21, 23, 26, 27, 28, 29, 30, 
31, 32, 33, 34, 35, 38, 41, 43, 44, 47, 52 
Fetal cord blood and pH   38 16, 17, 27, 34, 36, 44, 47 
Apgar scores (5 and/or 10 min)  N/A 22, 29, 30, 31, 32 
Anthropometric measures (birth 
weight, length, and/or head 
circumference) 
28 16, 17, 20, 21, 22, 23, 24, 25, 26, 27, 29, 
30, 31, 32, 33, 34, 35, 38, 39, 40, 43, 44, 
47, 52 
Fecal microflora samples  19, 43 23, 47, 51 
Abbreviation: N/A, not available. 
aEach number represents a study reviewed and its location in the reference list. 




Because there is an association between bacterial vaginosis and preterm labor, probiotics have a 
potential role in prevention.57 In a Cochrane review of prenatal probiotics to prevent preterm labor,57 
the results of Nishijima et al42 and Neri et al48 were pooled and it was found that probiotics reduced 
the risk of genital infection (particularly bacterial vaginosis) by 81% (OR: 0.19; 95% CI: 0.08-0.48, P = 
not reported). However, the authors concluded that there was not enough evidence to determine if 
probiotics reduced the incidence of preterm labor. 
More recently, Myhre et al50 evaluated the intake of probiotics and the risk of preterm labor in a large 
prospective cohort study. In addition to completing other questionnaires, women were asked to 
specify the quantity of probiotic milk products consumed (Table 3). Using logistic regression, the 
researchers found that women who reported a high intake of probiotic containing foods had a 
significantly lower risk of preterm labor (OR = 0.82; 95% CI: 0.681-0.986; P = .035). This study was 
limited by the use of recall questionnaires and a lack of clarity in reporting outcomes, but the authors 
concluded that probiotics may function by lowering the number of colonies of pathogenic bacteria and 
improving vaginal health, thereby limiting systemic inflammation that may play a role in the cascade of 
events that lead to preterm labor.57 Current data are insufficient to determine whether or not 
probiotics have a role in the prevention of preterm labor. 
Blood pressures and preeclampsia prevention 
The development and severity of preeclampsia appears to be related to both the maternal immune 
system and infections.58 Prenatal probiotics may reduce the placental and systemic inflammatory 
processes in ways that modify the maternal immune system to prevent preeclampsia.49 Maternal 
blood pressure was measured in 3 studies, among which 1 reported significant findings. Brantsaeter et 
al49 explored the relationship between probiotics and the risk of preeclampsia in primiparous women 
enrolled in a prospective cohort study. Although this study was limited by the use of dietary recall, the 
researchers found that daily probiotic intake significantly reduced the risk of preeclampsia (OR = 0.80; 
95% CI: 0.66-0.96; P = not reported). The risk of severe preeclampsia was significantly reduced by 
weekly (OR = 0.75; 95% CI: 0.57-0.98; P = not reported) or daily (OR = 0.61; 95% CI: 0.43-0.89; P = not 
reported) probiotic intake. These findings suggest that regular probiotics consumption during 
pregnancy may play a role in preeclampsia prevention. 
Glucose metabolism 
In an RCT conducted in Finland healthy pregnant nondiabetic women in the first trimester of pregnancy 
(N = 256) were randomized to 1 of 3 groups: (1) dietary counseling and probiotics, (2) dietary 
counseling and placebo, and (3) control and placebo. Dietary counseling included intensive instructions 
provided by a nutritionist to follow the recommended Nordic prenatal diet32 with special attention to 
sources of dietary fat and fiber, but no assessment of the subjects’ preintervention diets were 
reported. Laitinen et al30 found that women in the experimental group had a significantly lower mean 
plasma glucose level (OR = 0.31; 95% CI: 0.12-0.78; P = .013); the lowest insulin levels (adjusted means 
7.55, 7.32, and 7.27 mU/L; P = .032); and, during the last trimester, the highest index of insulin 
sensitivity obtained from a fasting sample (adjusted means 0.37, 0.35, and 0.35; P = .028). Luoto et 
al31 reported a significantly lower risk of gestational diabetes, 13% in the probiotics/diet group 
compared with a combined average of 35% across the placebo groups (P = .003). Aaltonen et al32 also 
reported a significantly lower incidence of gestational diabetes, 0% in the probiotics/diet group 
compared with a combined average of 10.8% in the placebo groups (P = .033). These studies were all 
limited by the use of participants’ dietary recall, yet these findings suggested that dietary counseling 
combined with probiotics could be used to both prevent and partially treat glucose disorders of 
pregnancy but more prospective study is needed. 
Body mass index and weight gain 
Because probiotics are considered food, the inclusion of weight gain as an outcome seems logical. 
While seven RCTs included body mass index (BMI) and/or pregnancy weight gain as study variables, 
only 2 prospective cohort studies from a single research collective reported statistically significant 
findings.49,50 Myhre et al50 found that women who consumed high levels of probiotic containing foods 
also had significantly lower prepregnant BMIs (P < .001) than those who consumed lesser amounts. 
Brantsaeter et al49 found that for women of normal prepregnant weight, there was no evidence that 
probiotics significantly altered overall maternal weight gain. More consistent inclusion of maternal 
prenatal and postpartum weight measurements in probiotics and prebiotics research is needed to 
guide clinicians. 
Gastrointestinal measures 
Because probiotics and prebiotics act on the mucosal surface of the gut, rectal swabs and fecal samples 
were used to assess changes in maternal intestinal colonization in 3 studies. While Lahtinen et al37 
found no difference in Bifidobacterium counts, the probiotic group had a significantly greater 
colonization of Lactobacillus rhamnosus (66.7%) than the placebo group (11.8%) (OR = 5.67; 95% CI: 
2.19-14.64; P < .001). By detecting the intervention probiotic in the maternal gastrointestinal tract, the 
researchers demonstrated that it survived the digestive processes of the upper tract and can benefit 
the mucosal surfaces of the colon. In the study by Schultz et al,51 L. rhamnosus was not detectible in 
rectal swabs done at 1 month postpartum in 3 of 6 women who took prenatal probiotics. Shadid et al47 
demonstrated a significant increase in the proportion of intestinal Bifidobacterium colony counts in 
women who took prebiotics compared with women in a placebo group (21% and 12.4%, respectively, P 
= .026). Because intestinal colonization with healthy bacteria has implications for both maternal and 
neonatal health, a more rigorous assessment of gastrointestinal measures would better inform clinical 
practice. 
Prenatal progesterone levels lead to a physiologic slowing of the maternal gastrointestinal tract. 
Probiotics are often used to improve gastrointestinal symptoms. Laitinen et al30 found pregnant 
women in both study groups reported minor gastrointestinal discomforts, such as flatulence, loose 
stools, or constipation at study initiation. Specifically 7% of the diet/probiotic, 8% in the diet/placebo, 
and 3% in the control/placebo groups reported these symptoms. Subsequently, because of the relative 
rarity of the symptoms, the researchers reported a combined prevalence of gastrointestinal symptoms, 
which were reduced to 2% in the second trimester and 0.5% in the third. This finding is clinically 
significant, because probiotic intake was not associated with any increase in the incidence of minor 
gastrointestinal discomforts in pregnant women, Gastrointestinal outcomes were not reported in most 
of the scientific investigations reviewed, representing a missed opportunity to attempt to address this 
important aspect of symptom management and quality of life during pregnancy. More investigation is 
needed to identify the impact of prenatal probiotics on the physiologic changes of pregnancy, such as 
constipation. 
Breast milk composition 
There is a suggestion in the literature that intestinal microflora play a role in breast milk composition.41 
Because there is a correlation between intestinal production of Transforming Growth Factor-beta (TGF-
β) (a cytokine associated with allergic sensitization) and the newborn’s ability to make Immunoglobulin 
A (IgA) antibodies and avoid allergies,17 these components in breast milk were evaluated in 6 studies. 
Three of the articles reported significant differences between groups. Rautava et al17 examined breast 
milk at 3 months postpartum while the mother was just finishing the probiotic or placebo treatment. 
The researchers found that the concentration of TGF-β2 was higher in the breast milk of probiotic 
group mothers than in that of controls (P = .018). In Bottcher et al,41 probiotics were administered only 
until the time of birth. There was no significant difference in breast milk IgA between groups, although 
significantly lower levels of TGF-β2 were identified in the breast milk of women who had the probiotic 
intervention (L. reuteri) found in their feces, compared with controls (P = .04). Probiotic treated 
women also had higher Interleukin 10 (IL-10) (an anti-inflammatory cytokine) in colostrum than 
controls (P = .046). However, neither difference was sustained in breast milk samples taken at 1 month 
postpartum. While the TGF-β2 findings of Bottcher et al41 contradicted those of Rautava et al,17 both 
described their results as protective against atopic disease development. 
In a 3-group RCT, Prescott et al38 studied women ingesting 2 different probiotics compared with a 
placebo and measured breast milk immune markers. The breastfeeding women continued the 
probiotic or placebo through 6 months postpartum. Prenatal Bifidobacterium lactis ingestion resulted 
in significantly higher TGF-β1 levels in early (1 week) breast milk (P = .028).  At 1 week, women in both 
probiotic groups also had significantly higher levels of IgA in breast milk (B. lactis, P = .008; L. 
rhamnosus, P = .011). At 3 months, only women in the B. lactis group had significantly higher levels of 
breast milk IgA (P = .027). It appears that probiotic supplementation during breastfeeding may result in 
at least some important immunologic benefits for the neonate, but to sustain these changes, 
continued probiotic ingestion may be needed. Because most of the studies were conducted in 
Northern Europe, where breastfeeding rates are high, it may be a missed opportunity that only a few 
studies examined breast milk composition. 
Maternal immunomarkers 
Significant findings related to maternal immunomarkers following probiotic administration were found 
in 2 RCTs. Boyle et al36 found that prenatal administration of L. rhamnosus significantly decreased 
human interferon γ (IFN-γ ) (a protein released as part of the immune response to pathogens) (P = .02). 
Asemi et al46 found that Lactobacillus acidophilus and Bifidobacterium animalis administration during 
pregnancy significantly decreased the serum level of highly sensitive C-reactive protein (a marker for 
inflammation) (P = .001). Proinflammatory factors are increased during pregnancy and these factors 
are associated with insulin resistance and pregnancy complications such as gestational diabetes, 
premature birth, and preeclampsia.46 These factors need to be included as outcomes in future 
investigations to better elucidate probiotic mechanisms of action. 
Neonatal outcomes 
In Table 4, all of the neonatal outcome categories are summarized with relevant references. 
Throughout this integrative review, details of statistically significant findings are presented. Although 
examination of neonatal outcomes revealed numerous statistically nonsignificant findings, a number of 
these outcomes are clinically relevant and therefore important to providers and their clients. It is 
possible that the absence of significant differences between groups may underscore the safety of 
prenatal probiotic exposure for the offspring. 
Gestational age at birth 
Variations in the timing of probiotic initiation reported among the studies limited the examination of 
the impact of prenatal probiotics on preterm birth prevention. However, gestational age at birth was 
included as a neonatal outcome in more than one-half of the studies and no significant differences 
were found between probiotic and control groups. In one metaanalysis,52 a nonsignificant increase in 
gestational age of 0.4 weeks in the infants of women in the probiotic versus control groups (P = .336) 
was found. Current evidence does not suggest an association between antenatal probiotics and 
clinically relevant differences in gestational age. 
Fetal cord blood and pH 
Researchers in 8 of the studies reviewed attempted to examine the prenatal use of probiotics or 
prebiotics for reducing the expression of immunoglobulin E antibodies associated with the 
development of atopic disease in children. However, as previously described, the long-term measures 
extended beyond the neonatal period and the parameters established for this integrative review. Only 
Prescott et al38 reported significant between-group differences in cord blood markers of allergic 
response. There was significantly less soluble cluster of differentiation 14 (a cell marker of atopic 
disease) in B. lactis group neonates (P = .045) and higher levels of interferon-γ cytokine in L. rhamnosus 
group neonates (P = .030) compared with the placebo group. The authors concluded that probiotics 
may modify cytokines and other parameters that play a role in neonatal immune responses. Only in the 
investigation of prebiotics did the researchers47 measured cord pH; no differences were found 
between prebiotic and control group neonates. The lack of consistent markers and the inclusion of 
women at risk for atopic disease limits the generalizability and utility of these findings. 
Apgar scores 
Apgar scoring is a universal neonatal measure that indicates the need for immediate newborn 
resuscitation.59 Investigators in only 6 of the studies reviewed explored 5- and/or 10-minute Apgar 
scores and reported no significant differences. With so little attention given to Apgar scores, there is 
insufficient evidence to draw conclusions about this outcome. 
Anthropometric measures 
Investigators in 24 of the studies reviewed included at least 1 newborn anthropometric measure (birth 
weight, length, and/or head circumference), and all but 2 reported no significant differences between 
groups. Huurre et al28 reported a significant difference in birth weight and length, with probiotic group 
infants averaging 170 g lighter (P < .05) and 0.6 cm shorter (P < .05). The weight difference 
(approximately 6 ounces) might be clinically significant for some dyads, while the shorter length (0.2 in) 
is unlikely to have an impact. A contradictory finding was reported in a meta-analysis,52 in which there 
was a nonsignificant trend toward larger birth weights (45 g increase or 1.6 ounces) in probiotic infants 
than in controls (P = .699). 
Without consistent information provided about birth weights in the studies reviewed, it is impossible 
to determine whether the incidence of low-birth-weight infants is impacted by probiotics or 
prebiotics.52 Only limited information on birth weight ranges was reported in one-half of the studies 
reviewed. The incidence of low birth weight was not reported by any investigators. Therefore, 
information is insufficient to draw conclusions about the impact of prenatal probiotics and prebiotics 
on low birth weight, although analysis of this aspect would be important to include in future work.52 
Luoto et al31 investigated prenatal and postnatal infant growth using maternal antepartal dietary 
modifications and probiotics in women with gestational diabetes. When analyzed by neonatal birth 
weight and length, significantly more infants of control group mothers with gestational diabetes were, 
on average, both heavier (426 g) and longer (1.7 cm) (P = .001) than probiotic exposed infants. This 
difference is also clinically significant as it amounts to nearly a pound lighter for probiotic group infants 
of diabetic mothers. Therefore, among women with gestational diabetes, findings suggest a possible 
protective effect against macrosomia. Because neonatal anthropometrics often play a role in birth 
outcomes, inclusion of these measures in sufficient detail in future interventional studies of prenatal 
probiotics and prebiotics would be simple yet meaningful. 
Fecal microflora samples 
Enhancement of neonatal gut microflora is one goal of prenatal probiotic ingestion. In 5 investigations 
reviewed, neonatal fecal samples were tested for the presence of probiotic bacteria. The investigators 
were attempting to identify if the probiotic bacteria ingested by the mother prenatally could be 
retrieved from neonatal fecal samples. Authors of 2 of the studies found significant between-group 
differences in fecal bacteria. Gueimonde et al19 analyzed neonatal fecal samples at 5 days of age and 
found significantly more B. breve in probiotic group neonates than in controls (P = .044), while B. 
adolescentis was significantly higher in placebo group neonates (P = .043). These differences were not 
significant in the 3-week stool samples (P = .069), but the researchers found that the intestinal 
microflora of neonates whose mothers took probiotics were more complex and less similar to their 
mothers. Niers et al43 examined neonatal stools weekly during the first month of life and found that 
colonization with Lactococcus lactis was significantly increased in the feces of probiotic group neonates 
at 2 weeks (P < .01), and at 3 to 4 weeks of life (P < .001). However, there were no significant 
differences in Bifidobacterium counts between groups in this study. While Bifidobacteium 
predominates in a healthy gut, it takes several months to fully develop during infancy.60 
Because the bacterial flora of the neonatal gut is markedly affected by mode of birth, environmental 
exposures, and feeding methods, interpretation of gastrointestinal outcomes of probiotic and prebiotic 
use must be examined within those contexts.61 The presence of Bifidobacterium and overall bacterial 
complexity and diversity are important indicators of a healthy neonatal intestinal microbiota.19 These 
measures were omitted in most of the studies reviewed; more in depth, long-term study is needed. 
Adverse effects of probiotics and prebiotics 
No adverse effects attributable to the use of prenatal probiotics or prebiotics were reported by 
investigators in any of the studies reviewed. In 1 article, neonatal morbidities such as jaundice, 
hypoglycemia, infection, the need for supplemental oxygen administration, and other more rare 
complications were not significantly different between probiotic and control group neonates.24 Allen et 
al45 focused on adverse events as the primary study outcome tracked using World Health Organization 
International Statistical Classification of Disease Criteria and questionnaires completed by mothers and 
providers. Adverse events such as infections and diseases of the nervous, respiratory, and digestive 
systems were reported by 15 women (6.8%) in the probiotic group compared with 21 (9.0%) in the 
placebo group, but these differences were not statistically significant. Overall, no negative sequelae 
were attributed to prenatal probiotics or prebiotics.45 
In healthy individuals, probiotics are not thought to be systemically absorbed.62 Although probiotic 
bacteria such as Lactobacillus are “generally regarded as safe,”2,63 and were included in nearly all of the 
study probiotic interventions, some concerns persist. For example, there are theoretical risks of 
probiotics for pregnant women and neonates due to their slightly compromised immune responses.53 
The development of serious infections in immune-compromised patients exposed to probiotics is 
considered possible.53 Prebiotic use would not introduce strains of new bacteria and therefore should 
pose no potential risk.53 In summary, no evidence of adverse effects of prenatal probiotics or prebiotics 
were documented in this review. 
DISCUSSION 
More than one-half of the prenatal probiotic studies reviewed were conducted for the purpose of 
reducing atopic disease in children. Prenatal probiotics have a well-established record of significantly 
reducing the incidence and severity of atopic disease in offspring.5 Unfortunately, many maternal and 
neonatal outcomes were largely ignored in the research studies reviewed, highlighting missed 
opportunities to build a strong body of perinatal evidence about the intervention. 
Summary of statistically significant findings 
Overall, few statistically significant maternal and neonatal outcomes associated with prenatal probiotic 
use were reported among the studies reviewed. However, the statistically significant maternal 
outcomes of prenatal probiotic ingestion are detailed as follows: reduced rates of bacterial 
vaginosis,48,57 increased vaginal bacterial colony counts of Lactobacillus,42 increased intestinal 
colonization with L. rhamnosus,37 lowered the incidence of preeclampsia,49 lowered the incidence of 
gestational diabetes,31,32 improved glucose metabolism,30 altered immune markers in serum,36,46 and 
those in breast milk17,38,41 and, when taken in high amounts, according to one prospective cohort50 
study and a Cochrane review,57 may reduce the risk preterm labor. Prebiotics significantly increased 
maternal Bifidobacterium in the intestines.47 
Similarly for the neonate, prenatal probiotics were associated with significantly higher intestinal 
colonization with Bifidobacterium19 and Lc. Lactis.43 Prenatal probiotics also modified several cord 
blood38 immunomarkers, placental cytokines, and other protective and/or growth promoting factors.27 
Limitations 
This integrative review has several limitations. First, it was difficult to determine with precision how 
the investigators analyzed specific measures and variables. A number of the studies reviewed did not 
contain clear reporting of statistics and/or between-group differences on maternal and neonatal 
outcomes. Despite careful consideration of the research collectives, some of the perinatal outcomes 
may have been overrepresented due to the inclusion of secondary analyses. Furthermore, even when 
authors did clearly indicate that they were using a subsample of a larger, earlier study, the number of 
women who were exposed to probiotics during pregnancy may be overestimated. The use of atopy as 
an eligibility criterion in more than one-half of the studies reviewed threatens the generalizability of 
the findings. In addition, the investigators used a variety of probiotics. There is emerging evidence that 
the effect of probiotics is strain specific and the findings from the use of one probiotic may not be 
attributable to another.8 Finally, given that there was only 1 study of prebiotics, conclusions about 
perinatal outcomes of prebiotic administration are limited. 
Clinical implications 
Most of the probiotic interventions were initiated in the third trimester and included once daily oral 
dosing with a probiotic containing Lactobacillus, and several added at least 1 Bifidobacterium. There 
was no evidence that taking probiotics beginning in the first trimester would be harmful. On the basis 
of the 2 prospective cohort studies, the use of live cultured milk products may be considered as a 
nutritional intervention valuable to all pregnant women. For example, the consumption of 
approximately 3 ounces of a cultured milk product daily was associated with a significant decrease in 
the risk of spontaneous preterm birth.50 The lowest risk of severe preeclampsia was associated with 
the consumption of approximately 7 ounces of cultured milk product daily.49 While these specific 
products may not be available in the United States, this review and the details provided could be used 
to select similar products that could meet the needs of pregnant women. When compared with the 
CFU dosing in most of the probiotic capsule supplements in the studies reviewed, substituting cultured 
milk products would require the consumption of large amounts to achieve a similar dosage. Because of 
the diversity of the studies reviewed, there is no single probiotic supplement that could be 
recommended universally to all pregnant women. 
Pregnancy is an opportune time for probiotic use because of the potential positive effects for the 
health of the woman and her neonate. Probiotics appear to hold promise for clinicians as 
nonpharmacologic, readily available, well-tolerated, low-risk therapies for women with minor 
complaints and may play a role in preventing major pregnancy complications. However, the maximal 
and immediate benefits for pregnant women appear to exist primarily during active probiotic 
ingestion, although the immunologic benefits for the infant exposed prenatally may persist for months 
or years.21 The outcomes of postpartum ingestion have not been clearly addressed in the scientific 
literature because several investigators continued probiotic ingestion for infants and sometimes for 
the mother during breastfeeding. On the basis of this review, prenatal probiotic and/or prebiotic use 
appears to be low risk and may lead to a variety of potential short- and long-term benefits for healthy 
women. 
The long-term safety for children born after probiotic use in pregnancy was evaluated by Luoto et al21 
at intervals up to 10 years of age. There were no adverse events or perinatal deaths in any women or 
infants involved in the study. While 26% of the study children exposed to probiotics during pregnancy 
were lost to follow-up and many of the outcomes were beyond the parameters for this review, the 
researchers concluded that probiotics did not significantly alter the duration of pregnancy, the mode of 
birth, prenatal or postnatal growth, rates of sepsis, Apgar scores, or the duration of breastfeeding. 
Research implications 
Detailed information about the effect of prenatal probiotics and prebiotics is vital for researchers, 
clinicians, and parents. There is emerging evidence that probiotics inhibit pathogens in the human 
microbiome.7,8 For example, an in vitro study showed that a probiotic composed of Lactobacillus and 
Bifidobacterium inhibited Group B Streptococcus growth64; this finding needs in vivo testing. 
Future research with a focus on more clarity and inclusion of consistent maternal and neonatal 
outcomes and measures is needed to enhance the clinical utility of the findings. Apgar scoring, 
newborn weight ranges (with incidence of preterm birth and low birth weight) could readily be 
included. Explicit reporting of sample demographics and outcomes, such as vaginal flora and pH, 
intestinal microbiota, immune markers, and the incidence of minor adverse effects would better 
contribute to the body of knowledge. The heterogeneity in outcome measures in this body of literature 
limits researchers’ abilities to conduct systematic reviews. Furthermore, analysis of between-group 
differences would facilitate replication and the conduct of meaningful meta-analyses. 
The omission of race as a demographic variable in all but 5 studies may be due to the fact that most 
were conducted in countries that have homogeneous populations. Because colonization with 
microbiota varies by race/ethnicity65 and geographic location,66 more research that explores the 
outcomes of prenatal probiotic use in diverse women from countries with heterogeneous populations 
is warranted. In addition, future investigations could be strengthened by including rationale for the 
choice of probiotics or prebiotics, the dose chosen, and the mode of administration. 
Well-controlled double blind trials of larger populations of healthy women (including those not at risk 
of atopic disease) are needed. Important clinical issues urgently need to be addressed, such as preterm 
labor prevention and promoting the establishment of healthy neonatal intestinal flora. The latter 
investigation requires controlling for mode of birth and type of infant feeding. The interactions 
between maternal and neonatal physiology were explored in only 11 studies.17–19,27,28,34,36,38,41,46,47 
Most of the research in this integrative review focused on long-term infant and pediatric outcomes. 
Critical measures during the transition from pregnancy through the first month of life, such as 
comparisons of maternal and neonatal intestinal flora,19 breast milk cytokines,17,18,28,41 other 
immunomarkers34,36,38,46,47 and placental fatty acids,27 were largely ignored. 
CONCLUSION 
In this integrative review, findings are presented on the clinical application of prenatal probiotics 
during pregnancy. Evidence was noted for the safety and tolerance of probiotics used during 
pregnancy, which is an opportune time to positively affect the long-term health of the developing fetus 
and child. Prenatal probiotics are associated with a decrease in atopic disease and may also have 
demonstrated impacts on other perinatal outcomes, although inconsistencies in measuring and 
reporting the outcomes limited the utility and generalizability of these findings. Only 1 study of 
prebiotics was found. Well designed and controlled clinical trials of diverse healthy women using well-
characterized strains of probiotics with rigorous assessment of the impact on intestinal and vaginal 
microbiota are needed to better determine clinically relevant perinatal outcomes. 
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